Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas C Krivak

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Obstetrics and Gynecology|March 3, 2007
Venous thromboembolism in obstetrics and gynecologyThomas C Krivak, Kristin K Zorn
Comprehensive Therapy|November 30, 2004
Tubo-ovarian abscess: diagnosis, medical and surgical managementThomas C Krivak, Christie Cooksey, Anthony M Propst
Gynecologic Oncology|March 25, 2021
Innovations in surgery and peri-operative care: A technical gimmick or true oncology advance?Christina Fotopoulou, Thomas C Krivak, Suk-Joon Chang
Obstetrical & Gynecological Survey|April 19, 2002
Insulinoma in pregnancy: a case report and review of the literatureCatherine A Takacs, Thomas C Krivak, Peter G Napolitano
Gynecologic Oncology|August 2, 2005
Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situBethanne Miller, James Dunn, John Dalrymple, et al.
Gynecologic Oncology|March 19, 2013
Upfront treatment of locally advanced cervical cancer with intensity modulated radiation therapy compared to four-field radiation therapy: a cost-effectiveness analysisJamie L Lesnock, Coreen Farris, Sushil Beriwal, et al.
Gynecologic Oncology|June 8, 2002
Port site metastasis of ovarian carcinoma remote from laparoscopic surgery for benign diseaseNicole L Carlson, Thomas C Krivak, William E Winter, et al.
American Journal of Obstetrics and Gynecology|April 27, 2010
Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancerLaura J Havrilesky, Thomas C Krivak, John W Mucenski, et al.
American Journal of Obstetrics and Gynecology|March 16, 2010
Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancerThomas J Herzog, Thomas C Krivak, Amanda Nickles Fader, et al.
Gynecologic Oncology|June 14, 2011
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancerJamie L Lesnock, Coreen Farris, Thomas C Krivak, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Obstetrics and Gynecology|March 3, 2007
Venous thromboembolism in obstetrics and gynecologyThomas C Krivak, Kristin K Zorn
Comprehensive Therapy|November 30, 2004
Tubo-ovarian abscess: diagnosis, medical and surgical managementThomas C Krivak, Christie Cooksey, Anthony M Propst
Gynecologic Oncology|March 25, 2021
Innovations in surgery and peri-operative care: A technical gimmick or true oncology advance?Christina Fotopoulou, Thomas C Krivak, Suk-Joon Chang
Obstetrical & Gynecological Survey|April 19, 2002
Insulinoma in pregnancy: a case report and review of the literatureCatherine A Takacs, Thomas C Krivak, Peter G Napolitano
Gynecologic Oncology|August 2, 2005
Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situBethanne Miller, James Dunn, John Dalrymple, et al.
Gynecologic Oncology|March 19, 2013
Upfront treatment of locally advanced cervical cancer with intensity modulated radiation therapy compared to four-field radiation therapy: a cost-effectiveness analysisJamie L Lesnock, Coreen Farris, Sushil Beriwal, et al.
Gynecologic Oncology|June 8, 2002
Port site metastasis of ovarian carcinoma remote from laparoscopic surgery for benign diseaseNicole L Carlson, Thomas C Krivak, William E Winter, et al.
American Journal of Obstetrics and Gynecology|April 27, 2010
Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancerLaura J Havrilesky, Thomas C Krivak, John W Mucenski, et al.
American Journal of Obstetrics and Gynecology|March 16, 2010
Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancerThomas J Herzog, Thomas C Krivak, Amanda Nickles Fader, et al.
Gynecologic Oncology|June 14, 2011
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancerJamie L Lesnock, Coreen Farris, Thomas C Krivak, et al.
Pageof 10